Skip to main content

Table 1 Comparison of patient characteristics between ACO and non-ACO COPD patients

From: Comprehensive analysis of allergen-specific IgE in COPD: mite-specific IgE specifically related to the diagnosis of asthma-COPD overlap

  ACO Non-ACO COPD Total P value
Subject (n) 34 42 76  
Sex male (%) 82.4 81.0 81.6 0.88
Body mass index (kg/m2) 24.1 ± 0.6 22.3 ± 0.6 23.1 ± 3.8 0.042*
Age (years) 72.5 ± 1.3 74.3 ± 1.2 73.5 ± 7.6 0.30
Smoking status (current/ex/never [%]) 20.6/79.4/0 7.1/90.5/2.4 13.2/85.5/1.3 0.16
Smoking history (pack-years) 55.7 ± 5.8 62.0 ± 5.2 59.2 ± 34.0 0.43
FVC, %predicted 107.6 ± 3.1 105.4 ± 2.8 106.4 ± 17.8 0.59
FEV1 (L) 1.68 ± 0.12 1.82 ± 0.10 1.76 ± 0.68 0.39
FEV1, %predicted 72.9 ± 4.1 79.6 ± 3.7 76.6 ± 24.2 0.24
FEV1/FVC ratio (%) 51.5 ± 2.4 57.1 ± 2.2 54.6 ± 14.1 0.088
RV, % predicteda 111.2 ± 5.1 112.8 ± 5.0 112.0 ± 27.2 0.82
DLco/VA, % predictedb 80.7 ± 5.7 72.6 ± 5.6 76.6 ± 30.9 0.32
Airway reversibility (mL)c 131.0 ± 23.1 102.9 ± 21.6 116.0 ± 105.6 0.38
Airway reversibility (%)c 9.3 ± 1.8 5.8 ± 1.7 7.4 ± 8.4 0.16
Blood eosinophil count (cells/μL) 248 ± 29 218 ± 26 231 ± 167 0.45
Serum total IgE (IU/mL) 375 ± 84 258 ± 75 310 ± 488 0.31
FeNO (ppb)d 33.8 ± 2.6 20.7 ± 2.3 26.4 ± 16.1 < 0.01**
ICS use before diagnosis of ACO (%) 35.3 7.1 19.7 < 0.01**
LABA (%) 85.3 73.8 79.0 0.22
LAMA (%) 82.4 81.0 81.6 0.88
Theophylline (%) 20.6 14.3 17.1 0.47
LTRA (%) 17.7 2.4 9.2 0.022*
Antihistamine (%) 14.7 7.1 10.5 0.29
  1. ACO asthma-COPD overlap, COPD chronic obstructive pulmonary disease, DLco/VA diffusing capacity of carbon monoxide/alveolar volume, FeNO fraction of exhaled nitric oxide, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, ICS inhaled corticosteroid, IgE immunoglobulin E, LABA long-acting β-agonists, LAMA long-acting muscarinic receptor antagonist, RV residual volume, LTRA leukotriene receptor antagonist
  2. aRV
  3. bDLco/VA (ACO n = 29, non-ACO COPD n = 30)
  4. cAirway reversibility (ACO n = 21, non-ACO COPD n = 24)
  5. dFeNO (ACO n = 33, non-ACO COPD n = 42)
  6. P < 0.05*, P < 0.01** between ACO and non-ACO COPD groups